HAYWARD, Calif.--(BUSINESS WIRE)--June 8, 2007--IMPAX
Laboratories, Inc. (OTC:IPXL) today announced that two poster
presentations, highlighting the company's compound, IPX054, a combined
immediate- and extended-release carbidopa/levodopa (CD/LD) product to
be marketed as VADOVA(TM), were presented at the Movement Disorder
Society's 11th International Congress of Parkinson's Disease and
Movement Disorders in Istanbul, Turkey on June 7, 2007. The poster
presentations will be available in the Investor Relations section of
the Company's Web site by clicking on Presentations.
Comparison of Pharmacokinetics and Pharmacodynamics of Combined
Immediate- and Extended-Release (IR+ER) Carbidopa/Levodopa
Formulations (VADOVA IR+ER) with IR Carbidopa/Levidopa and
Controlled-Release Carbidopa/Levodopa in Parkinson's Disease was
presented by lead researchers John Nutt, M.D and Peter A. LeWitt, M.D.
The study results concluded that at equivalent carbidopa/levodopa dose
level (50/200 mg), the combined immediate- and extended release
carbidopa/levodopa preparation produces a more rapid onset of clinical
response than controlled release carbidopa/levodopa, without the
higher peak plasma levodopa concentrations seen with immediate-release
carbidopa/levodopa 2x 25/100. The combined immediate- and
extended-release preparation may offer benefits in treating
Parkinson's Disease (PD) patients with motor fluctuations.
Bi-layer Formulation Of Carbidopa/Levodopa (IPX054) vs. Standard
Carbidopa/Levodopa In Stable PD Patients was presented by Christopher
G. Goetz M.D. Vanessa K Hinson, M.D. was a co-investigator of the
study. The study compared IPX054, a bi-layer tablet of immediate- and
extended-release carbidopa/levodopa (CD/LD) given twice daily vs.
standard CD/LD given four times daily in patients with stable PD. The
study results concluded that in stable PD patients without troublesome
dyskinesia, twice daily IPX054 provided comparable clinical efficacy
to CD/LD given four times daily based on objectively observed
assessments. Home-based video provided an objective means to assess
motor fluctuations. In this population, substitution with IPX054
maintains CD/LD efficacy and provides ease of administration which may
offer improved treatment compliance.
About The Movement Disorder Society
The Movement Disorder Society (MDS) gathers thousands of the
field's clinicians, researchers, trainees and industry supporters on
an annual basis at its International Congress of Parkinson's Disease
and Movement Disorders. This year it was held in Turkey at the
Istanbul Convention & Exhibition Centre on June 3-7, 2007. The purpose
of the MDS International Congress is to share ideas, encourage
interest among all those involved in the care and research of Movement
Disorders, to participate in the activities of MDS and to advance the
related clinical and scientific discipline. The target audience
includes clinicians, researchers, post-doctoral fellows, medical
residents and medical students with an interest in the current
research and approaches for the diagnosis and treatment of Movement
Disorders.
About IMPAX Laboratories, Inc.
IMPAX Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded products.
IMPAX markets its generic products through its Global Pharmaceuticals
division and markets its branded products through the IMPAX
Pharmaceuticals division. Additionally, where strategically
appropriate, IMPAX has developed marketing partnerships to fully
leverage its technology platform. IMPAX Laboratories is headquartered
in Hayward, California, and has a full range of capabilities in its
Hayward and Philadelphia facilities. For more information, please
visit the Company's Web site at: www.impaxlabs.com.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995:
To the extent any statements made in this news release contain
information that is not historical, these statements are
forward-looking in nature and express the beliefs and expectations of
management. Such statements are based on current expectations and
involve a number of known and unknown risks and uncertainties that
could cause IMPAX's future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Such risks
and uncertainties include, but are not limited to, possible adverse
effects resulting from the delisting of and suspension of trading in
IMPAX's stock, the SEC proceeding to determine whether to suspend or
revoke the registration of IMPAX's securities under section 12 of the
Securities Exchange Act, IMPAX's delay in filing its periodic reports
subsequent to its Form 10-Q for the third quarter of 2004, IMPAX's
ability to obtain sufficient capital to fund its operations, the
difficulty of predicting FDA filings and approvals, consumer
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, IMPAX's ability to successfully
develop and commercialize pharmaceutical products, IMPAX's reliance on
key strategic alliances, the uncertainty of patent litigation, the
availability of raw materials, the regulatory environment, dependence
on patent and other protection for innovative products, exposure to
product liability claims, fluctuations in operating results and other
risks detailed from time to time in IMPAX's filings with the
Securities and Exchange Commission. Forward-looking statements speak
only as to the date on which they are made, and IMPAX undertakes no
obligation to update publicly or revise any forward-looking statement,
regardless of whether new information becomes available, future
developments occur or otherwise.
CONTACT: IMPAX Laboratories, Inc.
Larry Hsu, Ph.D. President & CEO
510-476-2000, Ext. 1111
Arthur Koch, CFO, 215-933-0351
www.impaxlabs.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com
www.lhai.com
SOURCE: IMPAX Laboratories, Inc.